Statin adverse events in primary prevention: Between randomized trials and observational studies

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Considerable debate exists regarding who might benefit from statins for primary prevention. Statins have wide pleotropic effects, which contribute to their efficacy in lowering cardiovascular disease but may also result in adverse events (AEs). Caveats in identifying AEs in randomized controlled trials (RCTs) include the lack of a standardized definition of statin-associated AEs, the differences in properties of different statins, the selectivity of RCTs in choosing their participants, the presence of high rate of nonadherence/ withdrawal from trials and other concerns related to study design and conflict of interest. Caveats in identifying or overestimating AEs in observational studies include failure to identify baseline confounders, ascertainment bias, confounding by indication and healthy user bias. Statin use in observational studies may be a surrogate marker for higher socioeconomic standards, access to health care or use of other preventive services. Integrating evidence from both RCTs and observational studies is of paramount importance for appropriate patient-centered decision.

Original languageEnglish (US)
Pages (from-to)330-337
Number of pages8
JournalAmerican Journal of the Medical Sciences
Volume350
Issue number4
StatePublished - 2015

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Primary Prevention
Observational Studies
Randomized Controlled Trials
Conflict of Interest
Health Services Accessibility
Cardiovascular Diseases
Biomarkers

Keywords

  • Adverse events
  • Observational studies
  • Primary prevention
  • Randomized trials
  • Statin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{8e82af02b85d4dc2959fa53814ae2e2d,
title = "Statin adverse events in primary prevention: Between randomized trials and observational studies",
abstract = "Considerable debate exists regarding who might benefit from statins for primary prevention. Statins have wide pleotropic effects, which contribute to their efficacy in lowering cardiovascular disease but may also result in adverse events (AEs). Caveats in identifying AEs in randomized controlled trials (RCTs) include the lack of a standardized definition of statin-associated AEs, the differences in properties of different statins, the selectivity of RCTs in choosing their participants, the presence of high rate of nonadherence/ withdrawal from trials and other concerns related to study design and conflict of interest. Caveats in identifying or overestimating AEs in observational studies include failure to identify baseline confounders, ascertainment bias, confounding by indication and healthy user bias. Statin use in observational studies may be a surrogate marker for higher socioeconomic standards, access to health care or use of other preventive services. Integrating evidence from both RCTs and observational studies is of paramount importance for appropriate patient-centered decision.",
keywords = "Adverse events, Observational studies, Primary prevention, Randomized trials, Statin",
author = "Ishak Mansi and Palmer, {Biff F.}",
year = "2015",
language = "English (US)",
volume = "350",
pages = "330--337",
journal = "The American journal of the medical sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Statin adverse events in primary prevention

T2 - Between randomized trials and observational studies

AU - Mansi, Ishak

AU - Palmer, Biff F.

PY - 2015

Y1 - 2015

N2 - Considerable debate exists regarding who might benefit from statins for primary prevention. Statins have wide pleotropic effects, which contribute to their efficacy in lowering cardiovascular disease but may also result in adverse events (AEs). Caveats in identifying AEs in randomized controlled trials (RCTs) include the lack of a standardized definition of statin-associated AEs, the differences in properties of different statins, the selectivity of RCTs in choosing their participants, the presence of high rate of nonadherence/ withdrawal from trials and other concerns related to study design and conflict of interest. Caveats in identifying or overestimating AEs in observational studies include failure to identify baseline confounders, ascertainment bias, confounding by indication and healthy user bias. Statin use in observational studies may be a surrogate marker for higher socioeconomic standards, access to health care or use of other preventive services. Integrating evidence from both RCTs and observational studies is of paramount importance for appropriate patient-centered decision.

AB - Considerable debate exists regarding who might benefit from statins for primary prevention. Statins have wide pleotropic effects, which contribute to their efficacy in lowering cardiovascular disease but may also result in adverse events (AEs). Caveats in identifying AEs in randomized controlled trials (RCTs) include the lack of a standardized definition of statin-associated AEs, the differences in properties of different statins, the selectivity of RCTs in choosing their participants, the presence of high rate of nonadherence/ withdrawal from trials and other concerns related to study design and conflict of interest. Caveats in identifying or overestimating AEs in observational studies include failure to identify baseline confounders, ascertainment bias, confounding by indication and healthy user bias. Statin use in observational studies may be a surrogate marker for higher socioeconomic standards, access to health care or use of other preventive services. Integrating evidence from both RCTs and observational studies is of paramount importance for appropriate patient-centered decision.

KW - Adverse events

KW - Observational studies

KW - Primary prevention

KW - Randomized trials

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=84942789057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942789057&partnerID=8YFLogxK

M3 - Article

C2 - 26181083

AN - SCOPUS:84942789057

VL - 350

SP - 330

EP - 337

JO - The American journal of the medical sciences

JF - The American journal of the medical sciences

SN - 0002-9629

IS - 4

ER -